• Nigel S B Rawson and Kenneth I Kaitin.
• Center for Health Care Policy and Evaluation, Eden Prairie, MN 55344-7302, USA. nigel_rawson@uhc.com
• Ann Pharmacother. 2003 Oct 1; 37 (10): 1403-8.

BackgroundApproval times of new drugs are frequently longer in Canada than in the US, but it has been argued that reducing approval times might lead to unsafe drugs receiving marketing approval.ObjectiveTo compare new drug approval times in Canada and the US over a 10-year period and to relate them to safety discontinuations.MethodsApplication and approval dates of all new drugs except diagnostic products, new salts, esters, isomers, and dosage forms of already-marketed drugs, as well as combinations containing previously approved substances approved in the US and Canada between January 1992 and December 2001 were obtained from the respective drug regulatory agencies and other sources. Information about drugs discontinued for safety reasons was obtained from the agencies' publications and Web sites and from journal articles.ResultsNew drug approval times were significantly longer in Canada than in the US. The difference occurs in all drug categories and by review type (priority/standard). However, the proportion of new drugs approved and later discontinued for safety reasons from the Canadian market (2.0%) was just over half that in the US (3.6%).ConclusionsWhen serious drug safety problems were identified in a timely manner after US approval, the products were not subsequently approved in Canada. Canada avoided potential dangers because its longer approval times provided an opportunity to observe actual market experience in other countries. However, the trade-off is that new drugs, including those for conditions for which current therapy has limited efficacy, take significantly longer to be approved in Canada and, hence, to be available to Canadians.

21 keywords...

hide…